Articles published by Pfizer Inc.

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
September 22, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 19, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
September 19, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
September 18, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 12, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
September 11, 2023
From Pfizer Inc.
Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 05, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE


Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
August 30, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE



Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
August 14, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Reports Second-Quarter 2023 Results
August 01, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
July 27, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
July 21, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE



FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
June 27, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE


FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
June 23, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Declares Third-Quarter 2023 Dividend
June 22, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE


Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
June 20, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 06, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE



Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
May 30, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
May 25, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.